Article
Oncology
Gabriel B. Mpilla, Md Hafiz Uddin, Mohammed N. Al-Hallak, Amro Aboukameel, Yiwei Li, Steve H. Kim, Rafic Beydoun, Gregory Dyson, Erkan Baloglu, William T. Senapedis, Yosef Landesman, Kay-Uwe Wagner, Nerissa T. Viola, Bassel F. El-Rayes, Philip A. Philip, Ramzi M. Mohammad, Asfar S. Azmi
Summary: The study highlights the need for more effective targeted approaches to sensitize PNETs to everolimus for better treatment outcomes. The dual inhibitor KPT-9274 targeting PAK4-NAMPT, when combined with everolimus, showed promising results in inhibiting PNET growth and formation.
MOLECULAR CANCER THERAPEUTICS
(2021)
Article
Oncology
Chiara Alessandra Cella, Francesca Spada, Alfredo Berruti, Francesco Bertolini, Patrizia Mancuso, Massimo Barberis, Eleonora Pisa, Manila Rubino, Lorenzo Gervaso, Alice Laffi, Stefania Pellicori, Davide Radice, Laura Zorzino, Angelica Calleri, Luigi Funicelli, Giuseppe Petralia, Nicola Fazio
Summary: The early identification of resistant tumors remains a major challenge in the treatment of pancreatic neuroendocrine tumors (PanNETs). This study evaluated a specific angiogenesis panel as possible predictors of resistance to everolimus or everolimus efficacy in PanNETs. The findings suggest that circulating endothelial progenitors might be surrogate biomarkers for angiogenesis activity in PanNETs during everolimus treatment.
Article
Gastroenterology & Hepatology
Antonio Viudez, Guillermo Crespo, Maria Luisa Gomez Dorronsoro, Imanol Arozarena, Juan Jesus Marin-Mendez, Ana Custodio, Marta Benavent, Saioa Goni, Beatriz Garcia-Paredes, Jorge Hern, Maika Durantez, Vicente Alonso, Del Carmen Riesco, Carlos Lopez, Paula Jimenez-Fonseca, Borja Lopez San Vicente, Iranzu Gonzalez-Borja, Isabel Sevilla, Irene Hernandez-Garcia, Alberto Carmona-Bayonas, Jaume Capdevila, Jairo Perez-Sanz, Rocio Garcia-Carbonero, Leyre Perez-Ricarte, Marta Llanos, Ruth Vera, Ana De Jesus Acosta
Summary: Through immunohistochemistry expression evaluation, it was found that a simple immunohistochemistry prognostic score (IPS) could serve as an effective indicator for predicting the prognosis of patients with metastatic pancreatic neuroendocrine tumors treated with everolimus or capecitabine and temozolomide.
Review
Endocrinology & Metabolism
Praveen Dilip Chatani, Sunita Kishore Agarwal, Samira Mercedes Sadowski
Summary: PNETs are classified based on histologic differentiation and proliferative indices, with advances in high-throughput techniques allowing researchers to explore genetic alterations associated with malignant transformation. Clinical aggressiveness stratifies along other genotypic and phenotypic demarcations, impacting the potential molecular signatures, associated trials, and differences in responses to therapies for PNETs.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Radiology, Nuclear Medicine & Medical Imaging
C. Bezzi, P. Mapelli, L. Presotto, I Neri, P. Scifo, A. Savi, V Bettinardi, S. Partelli, L. Gianolli, M. Falconi, M. Picchio
Summary: Radiomics in the context of PanNETs focuses on methods, technical approaches, and clinical applications. Studies have shown potential in tumor grade prediction, differential diagnosis, and assessment of tumor behavior, but further validation and optimization are needed for clinical application.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Review
Biochemistry & Molecular Biology
Xin Lou, Yi Qin, Xiaowu Xu, Xianjun Yu, Shunrong Ji
Summary: This review examines the molecular fingerprints and heterogeneity of pancreatic neuroendocrine tumors (NETs), discussing the challenges of assessing heterogeneity through liquid biopsies and imaging modalities, as well as the challenges in treatment. Understanding intratumoral spatiotemporal heterogeneity is crucial for improving patient care.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2022)
Article
Oncology
Jordan M. Cloyd, George A. Poultsides
Summary: PNETs are a rare type of tumor originating from pancreatic islet cells, with surgical resection being the standard treatment for most patients and pancreas-preserving approaches being acceptable for smaller tumors. Observation is recommended for small, low-grade PNETs.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Biology
Vanessa Lakis, Rita T. Lawlor, Felicity Newell, Ann-Marie Patch, Andrea Mafficini, Anguraj Sadanandam, Lambros T. Koufariotis, Rebecca L. Johnston, Conrad Leonard, Scott Wood, Borislav Rusev, Vincenzo Corbo, Claudio Luchini, Sara Cingarlini, Luca Landoni, Roberto Salvia, Michele Milella, David Chang, Peter Bailey, Nigel B. Jamieson, Fraser Duthie, Marie-Claude Gingras, Donna M. Muzny, David A. Wheeler, Richard A. Gibbs, Massimo Milione, Paolo Pederzoli, Jaswinder S. Samra, Anthony J. Gill, Amber L. Johns, John Pearson, Andrew Biankin, Sean M. Grimmond, Nicola Waddell, Katia Nones, Aldo Scarpa
Summary: The study identified three subgroups of PanNETs with distinct methylation patterns and genotype characteristics. The T1 subgroup was enriched for functional tumors and wild-type genotypes, the T2 subgroup had mutations and recurrent chromosomal losses, while the T3 subgroup harbored MEN1 mutations and histological parameters associated with better prognosis.
COMMUNICATIONS BIOLOGY
(2021)
Article
Oncology
Yusuke Kurita, Noritoshi Kobayashi, Kazuo Hara, Nobumasa Mizuno, Takamichi Kuwahara, Nozomi Okuno, Shin Haba, Motohiko Tokuhisa, Sho Hasegawa, Kensuke Kubota, Atsushi Nakajima, Yasushi Ichikawa
Summary: This study retrospectively evaluated the treatment outcomes of everolimus rechallenge in patients with pancreatic neuroendocrine neoplasms (PNENs). The findings suggest that everolimus rechallenge may be considered as an acceptable treatment option for advanced PNENs patients when no other drug treatment options are available.
Review
Oncology
Megan L. Sulciner, Thomas E. Clancy
Summary: Pancreatic neuroendocrine tumors (PNETs) are rare malignancies characterized by secretion of hormones. Tumor grade, determined by Ki67 proliferation index and mitotic index, is the primary prognostic indicator. Surgery is the main treatment for PNETs, with functional PNETs requiring resection for symptom control and potential cure, while nonfunctional PNETs are increasingly managed nonoperatively. Evidence supports surgical management of metastatic disease and primary tumor in the presence of widespread metastases. In this review, we discuss the evolving surgical management of local and metastatic PNETs.
Review
Oncology
Koen M. A. Dreijerink, Wenzel M. Hackeng, Aatur D. Singhi, Christopher M. Heaphy, Lodewijk A. A. Brosens
Summary: NF-PanNETs are a heterogeneous group of neuroendocrine tumors with highly variable clinical behavior, necessitating improved prognostic biomarkers and molecular profiling. NF-PanNETs displaying alpha cell characteristics are more likely to present unfavorable biomarkers, while those with beta cell characteristics often lack these markers.
JOURNAL OF PATHOLOGY
(2022)
Review
Medicine, Research & Experimental
Amy Chang, Scott K. Sherman, James R. Howe, Vaibhav Sahai
Summary: Pancreatic neuroendocrine tumors (PNETs) are a heterogeneous group of neoplasms with varying treatment options. The treatment approach depends on factors such as tumor stage, grade and differentiation, symptoms, tumor burden, and rate of progression. Recent advancements in treatment have positively impacted patient care and prognosis.
ANNUAL REVIEW OF MEDICINE
(2022)
Article
Medicine, General & Internal
He Tong, Miaomiao Wang, Jingjing Liu, Chuangen Guo, Zhongqiu Wang, Jianhua Wang, Xiao Chen
Summary: This study investigated the prevalence and associated factors of bone loss in patients with pancreatic neuroendocrine tumors (PNETs). The results showed a high prevalence of osteoporosis and low bone mass in PNET patients, with age and diabetes being associated factors for bone loss.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Eduardo A. Vega, Onur C. Kutlu, Sylvia V. Alarcon, Omid Salehi, Vera Kazakova, Olga Kozyreva, Jennifer A. Chan, Claudius Conrad
Summary: In patients with <= 2cm NF-PanNETs, tumor location in the pancreatic body or tail, tumor grade III-IV, and younger age were associated with nodal metastases and the presence of M1 disease. While watchful waiting may be appropriate for most patients, individualized risk stratification is suggested for younger patients with high grade (III-IV) body/tail tumors due to increased risk of metastatic disease.
JOURNAL OF GASTROINTESTINAL SURGERY
(2021)
Article
Oncology
Gregory Kaltsas, Charalambos Andreadis, Paraskevas Kosmidis, Dimitrios Mavroudis, Kalliopi Pazaitou-Panayiotou, Michail Vaslamatzis, Ilias Athanasiadis
Summary: This study evaluated the progression-free survival (PFS) and overall response rate (ORR) in chemotherapy-naive patients with unresectable or metastatic Grade 1-2 pancreatic neuroendocrine tumors (panNETs) treated with everolimus in routine care in Greece. The results showed that everolimus displayed clinical benefit and a predictable safety profile in this patient population.
ANTICANCER RESEARCH
(2022)